Business Wire

Bregal Milestone and Ridango Announce the Acquisition of uTrack Software Solutions

Share

Acquisition of the Irish software company to further enhance Ridango’s Automatic Vehicle Location offering

Bregal Milestone, a leading European software growth private equity firm, is pleased to share that, since announcing its strategic growth investment in Swedish global provider of mission-critical public transportation software Ridango AS (“Ridango”) last month, it has also agreed to acquire uTrack Software Solutions (“uTrack”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424607486/en/

Eamonn Hughes and Erki Lipre

Founded in 2011 by Eamonn Hughes and Conor Gildea, uTrack is a Dublin-headquartered software company providing a public transport data platform with a real-time analysis and predictive engine that feeds a suite of software services that annually supports nearly 3 billion passengers, over 5 million app users, 150,000+ drivers and 73,000+ vehicles.

uTrack‘s clients include some of the largest urban bus, intercity coach, and school transport providers across Ireland, the UK, and North America. The company’s suite of SaaS products: Origin, Unity & Rygo – enables operational excellence across a public transport business, mobile tools for a predominantly remote frontline workforce, and a transformative customer experience for passengers.

The acquisition of uTrack will aim to strengthen Ridango’s offerings by increasing capabilities for long-distance and school transport operators, expanding its presence in Western Europe and the US, and broadening its AVL product offering, particularly for the student and driver customer groups. The combined expertise of Ridango and uTrack will help further accelerate innovation with real-time connectivity, data-driven insights, and route optimisation, driving greater efficiency and improved experiences for both customers and operators.

Cyrus Shey, Managing Partner and Co-Founder at Bregal Milestone, commented, "We identified uTrack as a compelling strategic fit for Ridango given uTrack’s software platform, loyal and recurring customer base of market leading institutions, and complementary geographic presence, which made it a natural fit for the Ridango ecosystem. We’re excited to support this combination as it unlocks meaningful synergies and accelerates growth across both platforms."

Erki Lipre, Founder and CEO at Ridango, said, "The acquisition of uTrack represents a strategic leap forward for Ridango. By combining our strengths and complementary services, we will deepen Ridango’s AVL and analytics capabilities and significantly strengthen our position in key global markets. We are truly excited to welcome Eamonn, Conor, and the entire uTrack team to the Ridango family."

Co-founders of uTrack, Eamonn Hughes and Conor Gildea, added, "Joining forces with Ridango is an exciting milestone for uTrack. From day one, our mission has been to enhance the passenger and operator experience through technology. Partnering with Ridango allows us to accelerate that mission and scale our impact across Europe and North America while continuing to innovate with a shared vision for smarter, more sustainable transit."

The terms of the uTrack transaction were not disclosed and are conditional upon the completion of the Ridango transaction.

About Bregal Milestone

Bregal Milestone is a leading software private equity firm with c.€1.3 billion of capital raised since inception. The firm provides growth capital and operational support to build market-leading software companies. Bregal Milestone is part of Bregal Investments, a leading global investment platform with assets under management of over €19 billion. Bregal Milestone was recognised by GrowthCap as one of the Top Growth Equity Firms of 2024. For more information, visit www.bregalmilestone.com or follow us on LinkedIn.

About Ridango

Ridango is the software operating system of choice for public transportation providers globally, specializing in automated fare collection (“AFC”), real-time passenger information systems, automatic vehicle location tracking (“AVL”), and mobility-as-a-service (“MaaS”) technology. The company partners with transport authorities and operators to enhance the efficiency, accessibility, and sustainability of public transit for customers and operators alike.

About uTrack

With strong expertise in inter-city travel, uTrack provides the digital software tools, innovation and expertise that enable public transport companies across the world to improve their businesses and deliver more targeted, reliable services that meet the demands of whole communities by growing passenger ridership, loyalty and satisfaction with the latest generation of real-time passenger information technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250424607486/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye